Boston Scientific Revenue 2010-2023 | BSX
Boston Scientific annual/quarterly revenue history and growth rate from 2010 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Boston Scientific revenue for the quarter ending December 31, 2023 was $3.725B, a 14.9% increase year-over-year.
- Boston Scientific revenue for the twelve months ending December 31, 2023 was $14.240B, a 12.29% increase year-over-year.
- Boston Scientific annual revenue for 2023 was $14.24B, a 12.29% increase from 2022.
- Boston Scientific annual revenue for 2022 was $12.682B, a 6.68% increase from 2021.
- Boston Scientific annual revenue for 2021 was $11.888B, a 19.92% increase from 2020.
| Boston Scientific Annual Revenue (Millions of US $) |
|
|---|---|
| 2023 | $14,240 |
| 2022 | $12,682 |
| 2021 | $11,888 |
| 2020 | $9,913 |
| 2019 | $10,735 |
| 2018 | $9,823 |
| 2017 | $9,048 |
| 2016 | $8,386 |
| 2015 | $7,477 |
| 2014 | $7,380 |
| 2013 | $7,143 |
| 2012 | $7,249 |
| 2011 | $7,622 |
| 2010 | $7,806 |
| 2009 | $8,188 |
| Boston Scientific Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2023-12-31 | $3,725 |
| 2023-09-30 | $3,527 |
| 2023-06-30 | $3,599 |
| 2023-03-31 | $3,389 |
| 2022-12-31 | $3,242 |
| 2022-09-30 | $3,170 |
| 2022-06-30 | $3,244 |
| 2022-03-31 | $3,026 |
| 2021-12-31 | $3,127 |
| 2021-09-30 | $2,932 |
| 2021-06-30 | $3,077 |
| 2021-03-31 | $2,752 |
| 2020-12-31 | $2,708 |
| 2020-09-30 | $2,659 |
| 2020-06-30 | $2,003 |
| 2020-03-31 | $2,543 |
| 2019-12-31 | $2,904 |
| 2019-09-30 | $2,707 |
| 2019-06-30 | $2,631 |
| 2019-03-31 | $2,493 |
| 2018-12-31 | $2,561 |
| 2018-09-30 | $2,393 |
| 2018-06-30 | $2,490 |
| 2018-03-31 | $2,379 |
| 2017-12-31 | $2,409 |
| 2017-09-30 | $2,222 |
| 2017-06-30 | $2,257 |
| 2017-03-31 | $2,160 |
| 2016-12-31 | $2,191 |
| 2016-09-30 | $2,105 |
| 2016-06-30 | $2,126 |
| 2016-03-31 | $1,964 |
| 2015-12-31 | $1,978 |
| 2015-09-30 | $1,888 |
| 2015-06-30 | $1,843 |
| 2015-03-31 | $1,768 |
| 2014-12-31 | $1,887 |
| 2014-09-30 | $1,846 |
| 2014-06-30 | $1,873 |
| 2014-03-31 | $1,774 |
| 2013-12-31 | $1,838 |
| 2013-09-30 | $1,735 |
| 2013-06-30 | $1,809 |
| 2013-03-31 | $1,761 |
| 2012-12-31 | $1,820 |
| 2012-09-30 | $1,735 |
| 2012-06-30 | $1,828 |
| 2012-03-31 | $1,866 |
| 2011-12-31 | $1,848 |
| 2011-09-30 | $1,874 |
| 2011-06-30 | $1,975 |
| 2011-03-31 | $1,925 |
| 2010-12-31 | $2,002 |
| 2010-09-30 | $1,916 |
| 2010-06-30 | $1,928 |
| 2010-03-31 | $1,960 |
| 2009-12-31 | $2,079 |
| 2009-09-30 | $2,025 |
| 2009-06-30 | $2,074 |
| 2009-03-31 | $2,010 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $106.819B | $14.240B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $182.261B | 23.87 |
| Stryker (SYK) | United States | $123.641B | 29.61 |
| Medtronic (MDT) | Ireland | $110.900B | 15.70 |
| EssilorLuxottica (ESLOY) | France | $100.527B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.760B | 0.00 |
| Haleon (HLN) | United Kingdom | $37.671B | 27.50 |
| ResMed (RMD) | United States | $32.010B | 30.05 |
| Terumo (TRUMY) | Japan | $25.312B | 35.75 |
| Koninklijke Philips (PHG) | Netherlands | $25.036B | 19.40 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.603B | 15.72 |
| Baxter (BAX) | United States | $18.054B | 12.84 |
| Insulet (PODD) | United States | $11.278B | 50.01 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.977B | 0.00 |
| Demant (WILYY) | Denmark | $10.234B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.140B | 26.63 |
| BellRing Brands (BRBR) | United States | $7.808B | 36.57 |
| Lantheus Holdings (LNTH) | United States | $5.398B | 13.45 |
| Haemonetics (HAE) | United States | $4.886B | 24.17 |
| GN Store Nord (GNNDY) | Denmark | $4.400B | 24.71 |
| Perrigo (PRGO) | Ireland | $4.199B | 12.73 |
| Prestige Consumer Healthcare (PBH) | United States | $3.500B | 16.55 |
| Envista Holdings (NVST) | United States | $3.241B | 13.38 |
| QuidelOrtho (QDEL) | United States | $2.820B | 15.65 |
| Neogen (NEOG) | United States | $2.781B | 26.75 |
| Green Thumb Industries (GTBIF) | United States | $2.736B | 54.19 |
| TG Therapeutics (TGTX) | United States | $2.677B | 75.30 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.647B | 0.00 |
| ICU Medical (ICUI) | United States | $2.641B | 23.31 |
| Agios Pharmaceuticals (AGIO) | United States | $1.904B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.711B | 50.14 |
| Verano Holdings (VRNOF) | United States | $1.693B | 0.00 |
| InMode (INMD) | Israel | $1.553B | 8.25 |
| Warby Parker (WRBY) | United States | $1.536B | 0.00 |
| Owens & Minor (OMI) | United States | $1.431B | 12.47 |
| AdaptHealth (AHCO) | United States | $1.263B | 9.41 |
| National Vision Holdings (EYE) | United States | $1.174B | 37.35 |
| AtriCure (ATRC) | United States | $1.069B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.951B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.950B | 0.00 |
| Evolus (EOLS) | United States | $0.790B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.734B | 15.61 |
| Cresco Labs (CRLBF) | United States | $0.695B | 0.00 |
| Quanterix (QTRX) | United States | $0.645B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.634B | 14.91 |
| PetIQ (PETQ) | United States | $0.572B | 18.69 |
| Valneva SE (VALN) | France | $0.530B | 0.00 |
| Jin Medical (ZJYL) | China | $0.515B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.498B | 0.00 |
| Surmodics (SRDX) | United States | $0.463B | 28.97 |
| ZimVie (ZIMV) | United States | $0.459B | 39.12 |
| Biote (BTMD) | United States | $0.448B | 8.59 |
| OraSure Technologies (OSUR) | United States | $0.382B | 12.29 |
| Cerus (CERS) | United States | $0.370B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.364B | 0.00 |
| Zynex (ZYXI) | United States | $0.339B | 46.44 |
| MacroGenics (MGNX) | United States | $0.274B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.274B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.274B | 27.11 |
| Sanara MedTech (SMTI) | United States | $0.252B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.242B | 15.22 |
| Omeros (OMER) | United States | $0.217B | 0.00 |
| Veru (VERU) | United States | $0.195B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.190B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.187B | 0.00 |
| High Tide (HITI) | Canada | $0.178B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.172B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.171B | 0.00 |
| Eagleford Energy (GRUSF) | United States | $0.154B | 74.00 |
| InterCure (INCR) | Israel | $0.141B | 23.77 |
| FitLife Brands (FTLF) | United States | $0.140B | 22.57 |
| Jushi Holdings (JUSHF) | United States | $0.130B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.110B | 0.00 |
| Fonar (FONR) | United States | $0.103B | 8.83 |
| MariMed (MRMD) | United States | $0.099B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.098B | 0.00 |
| Chimerix (CMRX) | United States | $0.094B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.093B | 0.00 |
| Brainsway (BWAY) | Israel | $0.092B | 0.00 |
| Safety Shot (SHOT) | United States | $0.073B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.067B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.058B | 3.81 |
| Rockwell Medical (RMTI) | United States | $0.050B | 0.00 |
| Apyx Medical (APYX) | United States | $0.050B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.045B | 0.00 |
| United-Guardian (UG) | United States | $0.042B | 15.25 |
| ImmuCell (ICCC) | United States | $0.041B | 0.00 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| Bright Green (BGXX) | United States | $0.040B | 0.00 |
| Exagen (XGN) | United States | $0.028B | 0.00 |
| Nephros (NEPH) | United States | $0.022B | 0.00 |
| Agape ATP (ATPC) | $0.018B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.018B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.015B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.011B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.002B | 0.00 |
| Lucy Scientific Discovery (LSDI) | Canada | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.001B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| Bruush Oral Care (BRSH) | $0.000B | 0.00 | |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |